| Drug ID: | Drug52 |
|---|---|
| Drug Name: | Iron |
| CID: | 23925 |
| DrugBank ID: | DB01592 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | NO |
| Other Approved: | YES |
| Identifier: | NCT01017614, , NCT03441893 |
| Molecular Formula: | Fe |
| Molecular Weight: | 55.84 g/mol |
| Isomeric SMILES: | [Fe] |
| Synonyms: | IRON; 7439-89-6; Iron, elemental; Ferrum; Iron powder; Remko; Armco iron; Ferrovac E; Ancor B; hierro |
| Phase 0: | 4 |
| Phase 1: | 19 |
| Phase 2: | 46 |
| Phase 3: | 81 |
| Phase 4: | 92 |
| Description: | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt472 | 23925 | Iron | 3040 | HBA2 | Homo sapiens (human) | Activator | |
| dt473 | 23925 | Iron | 7037 | TFRC | Homo sapiens (human) | 16564538 | None |
| dt474 | 23925 | Iron | 54583 | EGLN1 | Homo sapiens (human) | 16649251 | None |
| dt475 | 23925 | Iron | 55869 | HDAC8 | Homo sapiens (human) | 16681389 | Cofactor |
| dt476 | 23925 | Iron | 51327 | AHSP | Homo sapiens (human) | 16901899 | None |
| dt477 | 23925 | Iron | 2395 | FXN | Homo sapiens (human) | 16911956 | None |
| dt478 | 23925 | Iron | 2495 | FTH1 | Homo sapiens (human) | 17070541 | None |
| dt479 | 23925 | Iron | 2237 | FEN1 | Homo sapiens (human) | 20622253 | None |
| dt480 | 23925 | Iron | 79661 | NEIL1 | Homo sapiens (human) | 20622253 | None |
| dt481 | 23925 | Iron | 252969 | NEIL2 | Homo sapiens (human) | 20622253 | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05581420 | Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy. | NA | UNKNOWN | Leiden University Medical Center | Inflammatory Bowel Diseases | DRUG: Ferrous fumarate|DRUG: MonoFer | Details |
| NCT05456932 | Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease | PHASE4 | UNKNOWN | Leiden University Medical Center | Inflammatory Bowel Diseases|Iron-deficiency|Iron … | DRUG: Intravenous iron|DRUG: Ferric maltol|DRUG: … | Details |
| NCT07141238 | Microplastic Analysis in Pediatric Inflammatory Bowel Disease | NULL | RECRUITING | Medical University of Gdansk | Crohn Disease|Pediatric Inflammatory Bowel Diseas… | OTHER: Environmental microplastic exposure | Details |
| NCT05225545 | Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis | PHASE3 | UNKNOWN | American University of Beirut Medical Center | Anemia, Iron Deficiency|Ulcerative Colitis | DRUG: Sucrosomial Iron|DRUG: Oral Iron | Details |
| NCT05176795 | Host-microbiota-environment Interactions | NULL | TERMINATED | University Hospital, Clermont-Ferrand | Juvenile Idiopathic Arthritis|Diabetes type1|Infl… | OTHER: Stool sample | Details |
| NCT04960826 | Study of an Environmental Risk Factor in Crohn's Disease | NULL | RECRUITING | University Hospital, Lille | Inflammatory Bowel Diseases | None | Details |
| NCT04587141 | Clinical Burden of Anemia in Inflammatory Bowel Disease: Therapeutic Trial | PHASE3 | UNKNOWN | Fondazione IRCCS Policlinico San Matteo di Pavia | Iron Deficiency Anemia|Inflammatory Bowel Diseases | DRUG: Sucrosomial iron|DRUG: Ferric Gluconate|DRU… | Details |
| NCT04565821 | Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe | NA | ACTIVE_NOT_RECRUITING | Massachusetts General Hospital | Inflammatory Disease|Permeability; Increased|Croh… | DEVICE: IPD Probe via TNIT | Details |
| NCT04318405 | Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE). | NULL | COMPLETED | Pierre Fabre Pharma AG | Iron-Deficiency Anemia|Iron-Deficiency | DRUG: Iron isomaltoside 1000 | Details |
| NCT07380022 | Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases. | NA | RECRUITING | University of Thessaly | IBD|Hypertension (HTN)|Multiple Sclerosis|Anemia|… | DIETARY_SUPPLEMENT: Dietary supplement interventi… | Details |
| NCT04123990 | Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel Disease | NA | UNKNOWN | VIFORFRANCE | Intestinal Disease | DIAGNOSTIC_TEST: Iron status testing | Details |
| NCT03872622 | Intestinal Response Patterns to Microbial Signals | NA | COMPLETED | Sheba Medical Center | CD - Crohn's Disease | OTHER: Blood tests, intestinal biopsies, stool sa… | Details |
| NCT03466983 | A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease | PHASE4 | COMPLETED | Pharmacosmos A/S | IBD | DRUG: Iron Isomaltoside|DRUG: Ferric Carboxymalto… | Details |
| NCT03457571 | Clinical Observational Study: IBD Patients With Restless-legs-syndrome and Iron Deficiency Syndrome | NULL | COMPLETED | Charite University, Berlin, Germany | Inflammatory Bowel Diseases|Restless Legs Syndrom… | None | Details |
| NCT03376230 | Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease | NULL | TERMINATED | University Hospital, Lille | Inflammatory Bowel Diseases | OTHER: Collect of blood, urines, and intestinal b… | Details |
| NCT03282903 | The PRognostic Effect of Environmental Factors in Crohn's and Colitis | NULL | COMPLETED | University of Edinburgh | Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… | None | Details |
| NCT03247816 | Feraccru® Real World Effectiveness Study in Hospital Practice ( FRESH ) | NULL | COMPLETED | Shield Therapeutics | Anemia, Iron Deficiency|Inflammatory Bowel Diseas… | None | Details |
| NCT03136419 | Microbiota and Immune microEnvironment in Pouchitis | NA | UNKNOWN | University of Padova | Pouchitis|Ulcerative Colitis|Ileal Pouch | DIETARY_SUPPLEMENT: Lactobacillus casei DG|DIETAR… | Details |
| NCT02965209 | European Novel Motorized Spiral Endoscopy Trial | NA | COMPLETED | Evangelisches Krankenhaus Düsseldorf | Disorder of Small Intestine|Gastrointestinal Hemo… | PROCEDURE: motorized spiral enteroscopy | Details |
| NCT02774057 | Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD | PHASE4 | UNKNOWN | American University of Beirut Medical Center | Iron Deficiency Anemia|Inflammatory Bowel Disease | DRUG: Captafer®|DRUG: Iron Sulfate | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 1.0 | Crohn's disease | An intestinal disease that involves inflammation located_in intestine. | disease of anatomical entity gastrointestinal system disease, intestinal disease, inflammatory bowel disease | Obiltoxaximab; Budesonide; Hydrocortisone acetate; Sulfasalazine; Ursodeoxycholic acid; Pegunigalsidase alfa; Imiglucerase; Bictegravir; Taliglucerase alfa; Etelcalcetide; Cimetidine; Desonide | Crohn's disease is a relapsing systemic inflammatory diseas… | Details |
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Capsule Endoscopy for Refractory Iron Deficiency Anemia in Crohn's Disease: Cap…
PMID: 29409826
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Rational Management of Iron-Deficiency Anaemia in Inflammatory Bowel Disease
PMID: 29342861
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geog…
Reply: Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractu…
PMID: 29314243
Year: 2018
Relationship Type:
Association
Score: 6.3
Should asymptomatic young men with iron deficiency anemia necessarily undergo e…
PMID: 29294595
Year: 2018
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Patients' beliefs about medicine may either reflect the necessity for treatment or concerns regarding the treatment. We explored the ext…
Re: Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures…
PMID: 29281128
Year: 2018
Relationship Type:
Association
Score: 6.3
Iron Supplementation-Induced Phosphaturic Osteomalacia: FGF23 is the Culprit
PMID: 29281120
Year: 2018
Relationship Type:
Association
Score: 6.3
Safety and efficacy of parenteral iron in children with inflammatory bowel dise…
PMID: 29266387
Year: 2018
Relationship Type:
Treatment
Score: 6.3
OBJECTIVES: Anti-tumor necrosis factor alpha (anti-TNF-α) agents are generally well tolerated, yet they can be associated with serious adverse event…
Are the estrogenic hormonal effects of environmental toxins affecting small int…
PMID: 29150304
Year: 2017
Relationship Type:
Association
Score: 6.3
Physical activity, by definition, is any skeletal muscle body movement that results in energy expenditure. In the last few decades, a plethora of sc…
Position paper: The potential role of optical biopsy in the study and diagnosis…
PMID: 29139480
Year: 2017
Relationship Type:
Treatment
Score: 6.3
OBJECTIVE: Research has shown that there is an association between Inflammatory Bowel Disease, anxiety and mood disorders, however little is known a…
Intravenous iron treatments for iron deficiency anemia in inflammatory bowel di…
PMID: 29032713
Year: 2017
Relationship Type:
Treatment
Score: 6.3
OBJECTIVE: The aim of the study was to analyze the effect of granulocyte and monocyte apheresis (GMA) with mesalazine for induction of remission in …
Management of inflammatory bowel disease-related anemia and iron deficiency wit…
PMID: 29019427
Year: 2017
Relationship Type:
Treatment
Score: 6.3
Interleukin-33 (IL-33) is a member of the IL-1 cytokine family that has been widely studied since its discovery in 2005 for its dichotomous function…
Environmental triggers in IBD: a review of progress and evidence
PMID: 29018271
Year: 2018
Relationship Type:
Treatment
Score: 6.3
PURPOSE OF REVIEW: Significant gaps in knowledge and utilization of vaccinations exist among practitioners providing care for patients with IBD. Thi…
[Environmental risk factors for induction of the inflammatory bowel disease]
PMID: 28989158
Year: 2017
Relationship Type:
Association
Score: 6.3
Not found
Environmental correlates of geographic divergence in a phenotypic trait: A case…
PMID: 28944021
Year: 2017
Relationship Type:
Association
Score: 6.3
BACKGROUND: Inflammatory bowel disease (IBD) has been associated with increased risk of osteopenia and osteoporosis. Several risk factors contribute…
Prevalence of iron deficiency without anaemia in inflammatory bowel disease and…
PMID: 28899570
Year: 2018
Relationship Type:
Association
Score: 6.3
BACKGROUND/AIMS: The transition of adolescents with inflammatory bowel disease (IBD) from pediatric to adult care requires a well-structured standar…
Enteroendocrine cells-sensory sentinels of the intestinal environment and orche…
PMID: 28853441
Year: 2018
Relationship Type:
Association
Score: 6.3
The intestinal epithelium must balance efficient absorption of nutrients with partitioning commensals and pathogens from the bodies' largest immune s…
Correction to: Carvalho et al., Prevalence of iron deficiency anemia and iron d…
PMID: 28853335
Year: 2017
Relationship Type:
Association
Score: 6.3
The Role of Environmental Factors in the Pathogenesis of Inflammatory Bowel Dis…
PMID: 28846760
Year: 2017
Relationship Type:
Clinical Trial
Score: 6.3
BACKGROUND: Inflammatory bowel disease (IBD), once considered to be a Western disease, is increasingly being reported from India and other Asian cou…
Retrospective review of effectiveness and safety of intravenous ferric carboxym…
PMID: 28844092
Year: 2017
Relationship Type:
Treatment
Score: 6.3
BACKGROUND & AIMS: Vitamin D at serum 25(OH)D concentrations above 100 nmol/L is associated with disease remission in patients with IBD, suggesting …
Comparative epigenetic and genetic spatial structure of the perennial herb Hell…
PMID: 28814406
Year: 2017
Relationship Type:
Association
Score: 6.3
Not found